Rodrigo Romero Feregrino

Dr. Rodrigo Romero Feregrino

Instituto para el Desarrollo Integral de la Salud, Mexico City, Ciudad de México, Mexico
+3
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
RRRaúl Romero-Cabello
Raúl Romero-Cabello
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON
Valeria Magali Rocha RochaValeria Magali Rocha Rocha
Valeria Magali Rocha Rocha
RFRaul Romero Feregrino
Raul Romero Feregrino
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
Background: Influenza has continued to be an important public health challenge, and the WHO recommends that countries consider vaccination for persons at high risk. Mexico has such a program, and we sought to determine its current situation. Material and Methods: This study has an ecological, longitudinal, and retrospective design based on secondary information on the acquisition and application of vaccines against influenza from official data from 2006 to 2022. Results: We found annual variability in the numbers of purchases and application of doses, with coverage of less than 90% of the total population every year; in addition, 17 million vaccines were not used in this period. Discussion: This study shows the situation of the program at the national level. Two institutions acquired fewer the vaccines, while one purchased more for its target population, but the necessary vaccinations were not acquired. On average, 1.7 million of the vaccines purchased annually were not used, but in some years, more vaccines were applied than were purchased in all of the institutions. We also observed that, between institutions, the vaccine coverage was very different, from 21% to 180%. On average, 6.2 million people were not vaccinated annually, between 16% and 22% of the target population, demonstrating low coverage. When we compared the coverage data that we calculated to the data published by the institutions, a great difference was observed. Conclusions: We found inconsistencies in the data, indicating their unreliability and potential disorganization within the program, as the target populations of each institution were not clear. In addition, the application data may have had reporting errors. Adequate coverage was not achieved, and the coverage was different from that reported in the official sources. We propose the implementation of different systems for control, evaluation, and access to the information of the program.

2 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
RRRaul Romero-Cabello
Raul Romero-Cabello
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON
RFRaul Romero Feregrino
Raul Romero Feregrino
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
JAJulieta Isabel Aguilar-Feregrino
Julieta Isabel Aguilar-Feregrino
Background: In recent years in Mexico, a decreased Bacillus Calmette and Guérin (BCG) coverage has been observed concomitantly with new cases of tuberculosis. Material and Methods: This study is a descriptive and analytical evaluation regarding both BCG vaccine acquisition and coverage as reported by official sources over a 16-year period (2006–2021). Results: We found that vaccine acquisition, dose application and coverage are highly variable each year. Coverage is 90% or higher, except for the 2017–2020 period. Discussion: According to our calculations, between 3,917,616 and 4,961,868 individuals did not receive the BCG vaccine. Coverage was lower than 90% during the last 4 years, whereas this value decreased to 21% in 2020. Except for the last 5 years, the amount of acquired doses surpassed the demand thus causing a considerable vaccine wastage. Conclusions: BCG vaccine coverage is low and many individuals remain unprotected. The access to this vaccine is difficult and the number of newly reported cases of tuberculosis have increased during the last years. Thus, it is necessary to establish vaccination campaigns aimed protect the population and also to deploy a nominal system to control coverage, acquisitions, and target population.

RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
RRRaúl Romero-Cabello
Raúl Romero-Cabello
RFRaul Romero Feregrino
Raul Romero Feregrino
PVPaulina Vilchis-Mora
Paulina Vilchis-Mora
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
MRMARIO ALFREDO RODRIGUEZ-LEON
MARIO ALFREDO RODRIGUEZ-LEON
Introduction: In 2008, Mexico initiated its national HPV vaccination program targeting adolescent girls. This study aims to evaluate the current status of the program, analyzing trends in vaccine acquisition, administration, and coverage over a 16-year period. Materials and Methods: A retrospective longitudinal study was conducted using secondary data from 2008 to 2023. Official records from three major public health institutions—IMSS, ISSSTE, and SSA—were reviewed to assess HPV vaccine procurement and administration. Results: Significant fluctuations were identified in the number of doses acquired, administered, and the corresponding coverage rates. A marked decline was observed between 2019 and 2021, followed by a sharp increase in 2022 and 2023. Over the entire period, an estimated 6.8 million doses were not administered to the intended target population. Furthermore, 2.6 million doses were administered in excess of the number officially acquired, indicating possible discrepancies in data reporting or vaccine inventory management. Discussion: The findings revealed substantial inconsistencies in vaccine procurement, administration, and coverage across institutions. While IMSS and ISSSTE consistently reported coverage below the theoretical target, SSA occasionally exceeded expectations, potentially compensating for deficits elsewhere. Nevertheless, national coverage remained inadequate in several years, with notable disparities between institutions. These gaps highlight systemic weaknesses in program coordination, planning, and data transparency, contributing to millions of unvaccinated individuals. Conclusions: This study offers a comprehensive analysis of Mexico’s HPV vaccination program, uncovering critical irregularities in its implementation. Challenges include inaccurate target population estimation, inconsistencies between vaccine acquisition and administration, and limited data reliability. Despite some progress in recent years, particularly in the post-pandemic years, the program requires urgent restructuring. This includes implementing a national catch-up strategy, expanding vaccine eligibility, and strengthening surveillance systems to ensure equitable and effective coverage toward the elimination of cervical cancer.

31 March 2023 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
RRRaúl Romero-Cabello
Raúl Romero-Cabello
RFRaul Romero Feregrino
Raul Romero Feregrino
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
BMBerenice Muñoz-Cordero
Berenice Muñoz-Cordero
SSSamuel Sevilla-Fuentes
Samuel Sevilla-Fuentes
Introduction: The impact of the coronavirus disease 2019 (COVID-19) pandemic has globally challenged health services, especially because when the pandemic first reached Mexico, in February 2020, there was no known effective and safe treatment. A treatment scheme was offered by the Institute for the Integral Development of Health (IDISA) in Mexico City from March 2020 to August 2021 when there were many patients with COVID-19. This report summarizes the experience managing COVID-19 with this scheme. Materials and Methods: This is a descriptive, retrolective study. The data was obtained from the case files of the patients who attended the IDISA from March 2020 to August 2021 with COVID-19. All the cases were treated with the scheme consisting of nitazoxanide, azithromycin, and prednisone. Various laboratory blood tests and chest computerized tomography scan were done. When indicated, supplementary oxygen, and another specific treatment were used. A standardized clinical recording was conducted for 20 days based on symptoms and systemic symptoms. Results: Based on the World Health Organization criteria, the patients were classified according to the disease severity: 170 mild, 70 moderate, and 312 severe cases. The outcome was the discharge of 533 patients after their recovery, 16 were excluded from the study, and 6 died. Conclusions: The use of nitazoxanide, azithromycin, and prednisone proved to be effective as it resulted in improvement of symptoms and in successful outcomes for the management of COVID-19 outpatients.

25 February 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
RDRoberto Debbag
Roberto Debbag
María L. Ávila-AgueroMaría L. Ávila-Aguero
María L. Ávila-Aguero
JBJosé Brea
José Brea
CTCarlos Arturo Arturo Espinal Tejada
Carlos Arturo Arturo Espinal Tejada
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
This second part of this expert panel review explores the broader impact of vaccines across the lifespan, emphasizing their role beyond immediate infection control. Vaccines not only extend life expectancy but also influence long-term health trajectories, particularly during the critical first 1000 days of life, where they prevent severe infections, disability, and mortality. They contribute to cancer prevention through vaccination against human papillomavirus and hepatitis B, reduce cardiovascular events and complications in individuals with chronic diseases, and protect against late-life functional decline. Furthermore, vaccines exert lasting effects on healthy aging by modulating inflammation and preserving independence, while proposed vaccination schemes illustrate the need for a comprehensive, life-course approach. Together with Part 1, which focused on immunosenescence and immune modulation, this closing installment underscores vaccination as a cornerstone of sustainable health policy, reinforcing its pivotal role in extending both lifespan and healthspan for future generations.

20 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RDRoberto Debbag
Roberto Debbag
María L. Ávila-AgueroMaría L. Ávila-Aguero
María L. Ávila-Aguero
JBJosé Brea
José Brea
CTCarlos Arturo Arturo Espinal Tejada
Carlos Arturo Arturo Espinal Tejada
RFRodrigo Romero Feregrino
Rodrigo Romero Feregrino
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
This second part of the expert panel review explores the broader impact of vaccines across the lifespan, emphasizing their role beyond immediate infection control. Vaccines not only extend life expectancy but also influence long-term health trajectories, particularly during the critical first 1000 days of life, where they prevent severe infections, disability, and mortality. They contribute to cancer prevention through immunization against human papillomavirus and hepatitis B, reduce cardiovascular events and complications in individuals with chronic diseases, and protect against late-life functional decline. Furthermore, vaccines exert lasting effects on healthy aging by modulating inflammation and preserving independence, while proposed immunization schemes illustrate the need for a comprehensive, life-course approach. Together with Part 1, which focused on immunosenescence and immune modulation, this closing installment underscores vaccination as a cornerstone of sustainable health policy, reinforcing its pivotal role in extending both lifespan and healthspan for future generations.